Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local GM-CSF Spraying for Autoimmune Pulmonary Alveolar Proteinosis
NCT06989333Phase 2Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in pulmonary alveolar proteinosis (PAP). Primary endpoint: Chest High-Resolution Computed Tomography at 12 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sargramostim
03
Conditions
pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on NCT06989333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989333.